Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
06 10 2020
Historique:
pubmed: 19 9 2020
medline: 21 10 2020
entrez: 18 9 2020
Statut: ppublish

Résumé

Respiratory failure in the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is hypothesized to be driven by an overreacting innate immune response, where the complement system is a key player. In this prospective cohort study of 39 hospitalized coronavirus disease COVID-19 patients, we describe systemic complement activation and its association with development of respiratory failure. Clinical data and biological samples were obtained at admission, days 3 to 5, and days 7 to 10. Respiratory failure was defined as PO

Identifiants

pubmed: 32943538
pii: 2010540117
doi: 10.1073/pnas.2010540117
pmc: PMC7547220
doi:

Substances chimiques

Biomarkers 0
Mannose-Binding Lectin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

25018-25025

Informations de copyright

Copyright © 2020 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Competing interest statement: T.E.M. is a member of the Scientific Advisory Board for Ra Pharmaceutical producing complement inhibitors. All other authors declare no competing interests.

Références

Mol Immunol. 2013 Dec 15;56(3):232-9
pubmed: 23787367
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Emerg Microbes Infect. 2015 May;4(5):e28
pubmed: 26060601
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
Lancet Respir Med. 2020 Oct;8(10):946-949
pubmed: 32444269
Immunol Rev. 2016 Nov;274(1):245-269
pubmed: 27782319
Ann Intern Med. 2006 Aug 15;145(4):247-54
pubmed: 16908915
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
J Infect Dis. 2005 May 15;191(10):1697-704
pubmed: 15838797
Circulation. 2020 Jun 2;141(22):1739-1741
pubmed: 32271624
Am Rev Respir Dis. 1988 Aug;138(2):368-75
pubmed: 3264125
J Allergy Clin Immunol. 2020 Jul;146(1):215-217
pubmed: 32417135
Emerg Microbes Infect. 2018 Apr 24;7(1):77
pubmed: 29691378
Clin Immunol. 2020 Jun;215:108450
pubmed: 32360516
Nat Methods. 2018 Nov;15(11):909-912
pubmed: 30377371
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Trends Immunol. 2007 Apr;28(4):184-92
pubmed: 17336159
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Br J Haematol. 2020 Jun;189(6):e227-e230
pubmed: 32369610
Nature. 2020 Jul 29;:
pubmed: 32726800
Nat Rev Immunol. 2020 Jun;20(6):343-344
pubmed: 32327719
mBio. 2018 Oct 9;9(5):
pubmed: 30301856
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
Immunol Rev. 2016 Nov;274(1):74-97
pubmed: 27782323
Mol Cell Proteomics. 2009 Feb;8(2):245-57
pubmed: 18796702
Mol Immunol. 2003 Sep;40(2-4):73-84
pubmed: 12914814
Crit Care Med. 2017 Aug;45(8):1317-1324
pubmed: 28538439
Blood. 2015 Jul 9;126(2):278-9
pubmed: 26160188
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
J Leukoc Biol. 2017 Jan;101(1):193-204
pubmed: 27581539
Nat Immunol. 2018 Apr;19(4):327-341
pubmed: 29507356
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Clin Immunol. 2020 Oct;219:108555
pubmed: 32771488
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Mol Immunol. 2017 Sep;89:10-21
pubmed: 28576323
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):935-41
pubmed: 16456095
Thromb Res. 2020 Jun;190:62
pubmed: 32305740
Rheumatology (Oxford). 2016 Jul;55(7):1337-9
pubmed: 27105662

Auteurs

Jan C Holter (JC)

Department of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.

Soeren E Pischke (SE)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway; s.e.pischke@medisin.uio.no.
Division of Emergencies and Critical Care, Oslo University Hospital, 0424 Oslo, Norway.
Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.

Eline de Boer (E)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.

Andreas Lind (A)

Department of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.

Synne Jenum (S)

Department of Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.

Aleksander R Holten (AR)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Acute Medicine, Oslo University Hospital, 0424 Oslo, Norway.

Kristian Tonby (K)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.

Andreas Barratt-Due (A)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Division of Emergencies and Critical Care, Oslo University Hospital, 0424 Oslo, Norway.
Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.

Marina Sokolova (M)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.

Camilla Schjalm (C)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.

Viktoriia Chaban (V)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.

Anette Kolderup (A)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Pharmacology, University of Oslo, 0315 Oslo, Norway.

Trung Tran (T)

Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.

Torleif Tollefsrud Gjølberg (T)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
Department of Pharmacology, University of Oslo, 0315 Oslo, Norway.
Department of Ophthalmology, Oslo University Hospital, 0424 Oslo, Norway.

Linda G Skeie (LG)

Department of Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.

Liv Hesstvedt (L)

Department of Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.

Vidar Ormåsen (V)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.

Børre Fevang (B)

Research Institute of Internal Medicine, Oslo University Hospital, 0424 Oslo, Norway.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.

Cathrine Austad (C)

Department of Internal Medicine, Vestre Viken Hospital Trust, 3004 Drammen, Norway.

Karl Erik Müller (KE)

Department of Internal Medicine, Vestre Viken Hospital Trust, 3004 Drammen, Norway.
Department of Clinical Science, Faculty of Medicine, University of Bergen, 5007 Bergen, Norway.

Cathrine Fladeby (C)

Department of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.

Mona Holberg-Petersen (M)

Department of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.

Bente Halvorsen (B)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Research Institute of Internal Medicine, Oslo University Hospital, 0424 Oslo, Norway.

Fredrik Müller (F)

Department of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.

Pål Aukrust (P)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Research Institute of Internal Medicine, Oslo University Hospital, 0424 Oslo, Norway.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.
Faculty of Health Sciences, K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, 9037 Tromsø, Norway.

Susanne Dudman (S)

Department of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.

Thor Ueland (T)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Research Institute of Internal Medicine, Oslo University Hospital, 0424 Oslo, Norway.
Faculty of Health Sciences, K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, 9037 Tromsø, Norway.

Jan Terje Andersen (JT)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.

Fridtjof Lund-Johansen (F)

Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
ImmunoLingo Convergence Centre, University of Oslo, 0315 Oslo, Norway.

Lars Heggelund (L)

Department of Internal Medicine, Vestre Viken Hospital Trust, 3004 Drammen, Norway.
Department of Clinical Science, Faculty of Medicine, University of Bergen, 5007 Bergen, Norway.

Anne M Dyrhol-Riise (AM)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Infectious Diseases, Oslo University Hospital, 0424 Oslo, Norway.

Tom E Mollnes (TE)

Institute of Clinical Medicine, University of Oslo, 0315 Oslo, Norway.
Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
Faculty of Health Sciences, K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, 9037 Tromsø, Norway.
Research Laboratory, Nordland Hospital Bodø, 8092 Bodø, Norway.
Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7491 Trondheim, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH